Yescarta real-world evidence (RWE) study enrolment 2 years ahead of schedule
- Yescarta is the first CAR-T therapy approved by the FDA in the treatment of large B-cell lymphoma
- The Center for International Blood and Marrow Transplant Research and Kite study has reached it’s enrolment target of 1,500 patients 2 years early
- The FDA has required this long-term study for Yescarta which will follow the participants for at least 15 years, generating a wealth of RWE to assess long-term safety and effectiveness
Click here to learn more
SVMPharma is an innovative strategic consultancy, specialising in Real-World Evidence (RWE) for the pharmaceutical industry. SVMPharma generates RWE within UK and Europe through bespoke online Real-World Treatment Evaluators, leading to successful health technology appraisal (HTA) submissions. Clinical trial programmes do not reflect real-world clinical practice and outcomes, RWE supplements and enhances clinical datasets. SVMPharma’s specialist teams focus on delivering the outcomes that matter to your brand.